RegenXBio Inc. (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
$8.80
-$0.26(-3.11%)
At close: 4:00 PM EST
$8.80
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.04 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)869.05K
Market Cap
$447.48M
Enterprise Value$673.54M
Total Cash (Recent Filing)$230.07M
Total Debt (Recent Filing)$260.52M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
May 06, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding51,612,984
10 Day Avg. Volume555,434
30 Day Avg. Volume869,046
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue3.95
Enterprise Value/Gross Profit7.47
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$30.60Price Target Upside247.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$252.49M
Bulls Say, Bears Say
Bulls Say
Capitalization And PartnershipsA strong cash position, committed funding from AbbVie, and better-than-expected licensing and royalty revenues reduce near-term financing risk and help fund key development milestones.
Clinical TrialsTopline pivotal data for the Duchenne gene therapy is progressing toward reporting and could support regulatory approval and a material re-rating of the stock if results show clear clinical benefit.
Manufacturing And Regulatory ReadinessRGX-202 is being manufactured for commercial supply and a planned pre-BLA meeting with the FDA aims to align the company on filing strategy, potentially smoothing the path to a commercial submission.
Bears Say
Clinical Data VariabilityClinical results showed substantial variation across patients with some limited gains or declines, and the small sample size reduces confidence in treatment effectiveness ahead of pivotal readouts.
Financial PerformanceA sizable annual net loss underscores heavy development and operating costs and signals reliance on successful clinical outcomes or milestone payments to achieve sustainable profitability.
Regulatory And Safety ConcernsA complete response letter from the FDA and clinical holds after a brain tumor was identified in a related program have created regulatory uncertainty that could delay reviews or approvals for connected programs.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.04 and its highest was $16.19 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $447.48M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is May 06, 2026 which is in 27 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on Mar 05, 2026. The company reported -$1.3 earnings per share for the quarter, missing the consensus estimate of -$0.956 by -$0.344.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is -1.34.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 51,612,984 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of -$1.3 in its last earnings report, missing expectations of -$0.956. Following the earnings report the stock price went down -4.595%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.60 (247.73% Upside)
$30.60 (247.73% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 162.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.90%
12-Months-Change
Fundamentals
Return on Equity
-103.12%
Trailing 12-Months
Asset Growth
-2.78%
Trailing 12-Months
Company Description
RegenXBio Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong development and commercial catalysts: completed pivotal enrollment in Duchenne with differentiated efficacy and safety signals for RGX-202, substantial progress and promising outcomes in the Cirovec retinal programs (including large reductions in anti-VEGF injections and durable responses), an active AbbVie collaboration with a near-term $100M milestone, and solid revenue/financing transactions that support a runway into early 2027. Offsetting these positives are material regulatory setbacks in the MPS programs (CRL and clinical holds) driven by an AAV integration–associated tumor in one patient and biomarker/assay issues, plus higher R&D spend and reliance on milestone/monetization proceeds. Overall, the company appears to have multiple high-value, late-stage assets and funding pathways, but faces meaningful program-specific safety and regulatory risks that will need to be resolved.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$30.60
▲(247.73% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
9.23% Insiders
18.53% Mutual Funds
21.16% Other Institutional Investors
37.22% Public Companies and Individual Investors